Phase 1 Trial Finds TPIV200 Is Safe, Delays Recurrence in Ovarian, Breast Cancer

Phase 1 Trial Finds TPIV200 Is Safe, Delays Recurrence in Ovarian, Breast Cancer
An investigational vaccine called TPIV200 was found to be safe and generated strong T-cell immunity against tumor cells, significantly delaying recurrence in breast and ovarian cancer patients who had achieved complete responses in a Phase 1 trial. The study, “Folate Receptor Alpha Peptide Vaccine generates immunity in Breast and Ovarian Cancer Patients,” appeared in the journal

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *